COO

Business profile & competitive position

The Cooper Companies, Inc. (COO) sits in the Healthcare sector under the Medical - Instruments & Supplies industry. It is a global medical-device company headquartered in San Ramon, California, with two distinct operating segments. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses and specialty eyecare products, including silicone hydrogel lenses, orthokeratology/scleral lenses and the MiSight 1 day myopia-management lens. CooperSurgical provides more than 600 products and services focused on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor-and-delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services. Products are sold in over 130 countries and are described by management as positively impacting more than fifty million lives annually.

The margin profile reflects a business that generates solid, recurring cash flows but is not a capital-light compounder. The reported 13.5% net margin is healthy for a diversified medical-device manufacturer, while the modest 6.9% ROE suggests that retained capital is working harder than a pure margin number alone implies—possibly reflecting a larger asset base, goodwill from past acquisitions or a conservative leverage posture. Competitive insulation comes from a mix of protected products and scale: the MiSight 1 day lens is notable as the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow myopia progression in age-appropriate children. Still, the business remains a global device maker with meaningful manufacturing, distribution and regulatory commitments rather than a high-margin, asset-light franchise.

Financial posture

Against the current share price of $56.13, the company carries a $10.9 billion market capitalization and trades at a trailing P/E of 19.2. The net margin stands at 13.5%, while return on equity is 6.9%. The stock’s beta of 0.82 indicates slightly less market sensitivity than the broader equity benchmark, consistent with a defensive healthcare-device business.

The valuation multiple sits in a range that suggests the market is neither pricing in explosive growth nor distress. The 13.5% net margin supports the cash-generation narrative, yet the lower ROE relative to that margin points to either lower asset turnover or light leverage compared with peers that juice returns with debt. Short-term technical positioning is also worth noting: with a 50-day EMA near $64.65, the current price sits well below that average, and the RSI of 32.8 is approaching traditionally oversold readings. These are descriptive observations—not an investment stance—because the next catalyst is what typically resolves such gaps.

Strategic priorities & outlook

The company’s most recent 10-K outlines a clear operational playbook built around penetration, distribution, myopia education, and fertility/women’s health integration.

• CooperVision is focused on greater worldwide market penetration of recently introduced products and on expanding its presence in both existing and emerging markets.
• It is increasing investment in distribution and packaging capabilities to support growth and quality service.
• It is investing to develop the myopia management market by educating eye care practitioners, patients and their families—an effort that ties directly to MiSight’s regulatory positioning.
• CooperSurgical expects to continue investing in its business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health.

Management also calls out its global footprint and R&D base: approximately 500 research-and-development employees supporting both segments. The 10-K tone is therefore expansion-oriented—pushing new product rollout, supply-chain capacity and practitioner education rather than cost-cutting or retrenchment.

Macro & geopolitical exposure

As a Healthcare / Medical - Instruments & Supplies company with global manufacturing and sales in over 130 countries, COO is exposed to several macro themes that define the medical-device space.

• Regulatory and approval risk: lenses, fertility devices and surgical supplies must satisfy the FDA and foreign regulators such as China’s NMPA and Japan’s MHLW. Approvals create moats, but new standards or inspection delays can alter product rollouts.
• Currency translation: a large international revenue footprint makes results sensitive to the U.S. dollar’s strength versus the euro, yen, yuan and other currencies.
• Trade policy and tariffs: polymers, packaging materials and finished devices move through global supply chains, so changes in tariffs or trade restrictions can affect input costs and gross margins.
• Commodity and supply-chain expense: single-use medical supplies rely on specialty plastics, silicones and packaging resins, making cost and availability relevant inputs for margin stability.
• Demographics and reimbursement: myopia prevalence, aging populations, and access to fertility services influence demand, while public and private reimbursement policies affect end-user affordability.

These are structural characteristics of the medical-device industry; they are not company-specific predictions but are the categories investors typically monitor for COO-like names.

Recent developments

The recent news tape for the ticker has been dominated by shareholder-law-firm notices and unrelated “COO” headlines. On September 25, 2026, Globe Newswire published a release from The Rosen Law Firm encouraging investors who suffered losses in The Cooper Companies to contact the firm. On September 24, 2026, PR Newswire carried a similar investor-alert notice from the Pomerantz Law Firm investigating claims on behalf of Cooper Companies investors. These releases often follow sharp price declines and do not, by themselves, establish wrongdoing, but they do signal that at least some holders are scrutinizing the stock’s recent drop for actionable claims.

The same news window also included two headlines with the ticker “COO” used in a different sense. On September 26, 2026, Fool.com reported that an AST SpaceMobile chief operating officer sold 12,000 shares for roughly $707,000 amid a 47% one-year return, and on September 24, 2026, Fool.com noted that Bloom Energy COO Chitoori Satish sold shares for $775,072. Neither is related to The Cooper Companies; they illustrate the confusion that can arise when a ticker is also a common job title. For COO-the-stock, the relevant items are the law-firm alerts, which sit against the backdrop of the September 2026 post-earnings decline.

Earnings behavior & post-earnings drift

The Cooper Companies has delivered an 8-for-8 beat rate over the last eight reported quarters, with an average positive earnings surprise of 4.2%. Yet the average five-day move after those reports is -2.34%, classified as a downward post-earnings drift. That divergence—consistent beats paired with negative average follow-through—is the key behavioral pattern to understand for this ticker.

The last four quarters show just how noisy this relationship can be.

• September 9, 2026: actual EPS of $1.15 vs. the $1.12 consensus (+2.7% surprise). The stock fell 14.67% the next day and 13.97% over the following five sessions.
• June 4, 2026: actual EPS of $1.21 vs. the $1.10 estimate (+10.0% surprise). The stock rose 8.58% the next day and 8.85% over five sessions.
• March 5, 2026: actual EPS of $1.10 vs. the $1.03 estimate (+6.8% surprise). The stock dropped 4.55% the next day and 10.82% over five sessions.
• December 4, 2025: actual EPS of $1.15 vs. the $1.11 estimate (+3.6% surprise). The stock gained 5.67% the next day and 6.59% over five sessions.

Beating the consensus has clearly not guaranteed a positive price reaction. One explanation is that the “beat” becomes a low bar once management has consistently cleared it; traders then focus on guidance, gross margins, currency impacts or segment commentary. The most recent print is a textbook example: a 2.7% beat produced a double-digit drop, likely because forward commentary disappointed the market’s real expectation even though the backward-looking EPS line exceeded the published estimate.

The next earnings date is December 3, 2026, after the close, with a current consensus EPS estimate of $1.08. Given the 100% trailing beat rate and the -2.34% average five-day drift, the relevant question for event-driven readers is not just whether the company slips past the $1.08 estimate, but whether the guidance and segment narrative can avoid the kind of repricing seen after the September report.

For readers who want to move beyond the headline numbers, the next step is to look at the full institutional verdict—analyst estimate revisions, sector relative valuation, debt and free-cash-flow details, and how the current December 2026 consensus compares with management’s own historical guidance. Those inputs provide the deeper context behind the earnings numbers and price action described above. This discussion is for educational purposes only and is not a recommendation to buy, sell or hold the security.